EquiTrak Pro
Manufacturer: MedBalance GmbH, Frankfurt
Exclusive Distribution
In Negotiation
6 Territories
Deal Value
$2.4M
Y1 target
Term Length
5 Years
excl + renewal
Start Date
Jun 2026
projected
Taevas Margin
32%
target gross
78/100
AI Deal Health Score: 78/100Total Clauses
10
AI Flagged
2
Require Legal
2
Deal Risk
Medium
2 of 10 clauses flagged. 2 require legal review — Clause 2 and Clause 7. Overall deal structure favorable. Risk: Medium.